Apoptosis

The important discovery of the IAP family of animal cell death regulators by CHEO Research Institute investigators nearly two decades ago paved the way for a unique research centre that is focused on the understanding and manipulation of programmed cell death (apoptosis) to treat disease. The Apoptosis Research Centre (ARC) hosts several principal investigators who share a common goal of curing or improving the treatment of adult and childhood diseases, including cancer and diabetes, and genetic disorders such as Spinal Muscular Atrophy (SMA), Myotonic Muscular Dystrophy (DM), and Duchenne Muscular Dystrophy (DMD). All this work occurs in a highly collaborative environment with state-of-the-art cell and whole-body imaging instrumentation and with robotic high-throughput screening equipment, which helps identify key genetic factors that contribute to the disease process. The ultimate translation of the basic discoveries by ARC scientists into the clinic involves a wide range of approaches, including gene therapy, analysis of cell signaling pathways, identification and therapeutic assessment of small molecule compounds, and the investigation of “oncolytic” viruses that target cancer cells for death.

Related News

Research Projects

  1. Suspension-Induced Stem Cell Transition: A Non-Transgenic Method to Generate Adult Stem Cells from Mouse and Human Somatic Cells

    23/10/2022

    Our initial observations revealed that when fibroblasts are cultivated in suspension culture, they undergo a notable transformation in morphology and concurrently exhibit the expression of stem cell-associated markers. However, this intriguing phenomenon is transient, as these cells subsequently enter a phase of rapid apoptosis (anoikis or detachment-induced cell death). Therefore, we explored whether or not ASCs could be derived in larger numbers from suspensions of somatic cells cultured under non-adherent conditions. We initially studied mouse dermal fibroblasts (tail/ear fibroblasts, TEFs) [10] in novel suspension culture conditions together with newly formulated growth factor (GF)-enriched [11], serum-free culture media with the Rho-kinase inhibitor [12], designed to support the transformation, survival and proliferation of ASCs.

  2. SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases

    18/02/2020

    This may benefit and guide the development of SMs or selective RIPK inhibitors as anti-inflammatory therapeutics for various chronic inflammatory conditions.

  3. Acid Sphingomyelinase Inhibition Attenuates Cell Death in Mechanically Ventilated Newborn Rat Lung

    12/10/2018

    Ventilation-induced ceramides promote autophagy-mediated cell death, and identifies SMPD1 as a potential therapeutic target for the treatment of ventilation-induced lung injury in newborns.

  4. Smac Mimetics Synergize With Immune Checkpoint Inhibitors to Promote Tumour Immunity Against Glioblastoma

    01/02/2017

    Overall, this combinatorial approach could be highly effective in clinical application as it allows for cooperative and complimentary mechanisms in the immune cell-mediated death of cancer cells.

Researchers

  1. Tommy Michel Alain

    Senior Scientist, CHEO Research Institute

    View Profile Email
  2. Shawn Beug

    Scientist, CHEO Research Institute

    View Profile Email
  3. Kyle Cowan

    Scientist, CHEO Research Institute

    View Profile Email
  4. Robert P Jankov

    Senior Scientist, CHEO Research Institute

    View Profile Email
  5. Robert Korneluk

    Senior Scientist, CHEO Research Institute

    View Profile Email
  6. Eric LaCasse

    Associate Scientist, CHEO Research Institute

    View Profile Email
  7. Alex MacKenzie

    Senior Scientist, CHEO Research Institute

    View Profile Email
  8. Behzad Yeganeh

    Associate Scientist, CHEO Research Institute

    View Profile Email